Compare · APLM vs LLY
APLM vs LLY
Side-by-side comparison of Apollomics Inc. (APLM) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APLM and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.16T, about 15132.0x APLM ($76.7M).
- Over the past year, APLM is up 287.9% and LLY is up 67.6% - APLM leads by 220.2 points.
- LLY has been more active in the news (16 items in the past 4 weeks vs 6 for APLM).
- LLY has more recent analyst coverage (25 ratings vs 0 for APLM).
- Company
- Apollomics Inc.
- Eli Lilly and Company
- Price
- $23.00-9.73%
- $1233.40-1.12%
- Market cap
- $76.7M
- $1.16T
- 1M return
- +17.26%
- +3.00%
- 1Y return
- +287.86%
- +67.64%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 16
- Recent ratings
- 0
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest APLM
- Director Huang Ya-Chi converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 50% to 1,500 units (SEC Form 4)
- SEC Form D filed by Apollomics Inc.
- Chief Operating Officer Chen Yi-Kuei bought $300,000 worth of CLASS A ORDINARY SHARES (20,000 units at $15.00) (SEC Form 4)
- Chief Financial Officer Lin Peter Kuan-How bought $400,005 worth of CLASS A ORDINARY SHARES (26,667 units at $15.00), increasing direct ownership by 120% to 48,979 units (SEC Form 4)
- Chief Executive Officer Chen Hung-Wen bought $7,550,004 worth of CLASS A ORDINARY SHARES (536,667 units at $14.07), increasing direct ownership by 182% to 418,334 units (SEC Form 4)
- Apollomics Announces $10 Million Private Placement Transaction
- SEC Form 3 filed by new insider Yen Hung Hsien
- SEC Form 6-K filed by Apollomics Inc.
- SEC Form 6-K filed by Apollomics Inc.
- Apollomics Regains Full Compliance with Nasdaq Listing Requirements
Latest LLY
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,004 units (SEC Form 4)
- Director Luciano Juan R was granted 13 shares, increasing direct ownership by 0.08% to 16,918 units (SEC Form 4)
- Director Fyrwald J Erik was granted 8 shares, increasing direct ownership by 0.01% to 75,418 units (SEC Form 4)
- Director Alvarez Ralph was granted 10 shares, increasing direct ownership by 0.02% to 55,745 units (SEC Form 4)
- EVP & President, LLY Int'l Jonsson Patrik sold $7,638,150 worth of shares (6,500 units at $1,175.10) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 54,147 units (SEC Form 4)
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
- SVP, Finance, & CAO Zakrowski Donald A sold $2,370,020 worth of shares (2,000 units at $1,185.01) as part of a pre-agreed trading plan, decreasing direct ownership by 57% to 1,526 units (SEC Form 4)